Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Pasithea opens a new UAB clinical site for its Phase 1/1b PAS-004 NF1 trial and will serve as Platinum Sponsor of the 2025 NF Caregivers Symposium.